Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5704MR)

This product GTTS-WQ5704MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 1048
UniProt ID P07766; P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5704MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7155MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ14457MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ12847MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ5256MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ2228MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ3097MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ1514MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ13446MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW